首页> 美国卫生研究院文献>International Journal of Clinical and Experimental Pathology >The 8p11 Myeloproliferative Syndrome: Review of Literature and an Illustrative Case Report
【2h】

The 8p11 Myeloproliferative Syndrome: Review of Literature and an Illustrative Case Report

机译:8p11骨髓增生综合征:文献复习和例举病例报告

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The 8p11 myeloproliferative syndrome (EMS), also called stem cell leukemia/lymphoma (SCLL), is a relatively rare condition characterized in its typical form by the occurrence, either simultaneously or sequentially, of a bcr/abl-negative myeloproliferative disorder and a lymphoma, usually a precursor T lymphoblastic lymphoma. The disease most often terminates in acute myeloid leukemia which is resistant to conventional chemotherapy. The defining cytogenetic abnormality, a translocation at the 8p11 locus, always involves the fibroblast growth factor 1 (FGFR1) gene. To date, eight partner genes have been identified in association with FGFR1 rearrangements. The most frequent FGFR1 translocation partner is the zinc finger gene ZNF198 located at 13q11. The t(8;13)(p11;q11) disrupts intron 8 of the FGFR1 gene and fuses proline-rich and zinc finger domains of the ZNF198 gene with the cytoplasmic tyrosine kinase domain of FGFR1. Oligomerization of the fusion protein occurs, with subsequent activation of downstream signal transduction pathways, culminating in neoplastic cell transformation. This review describes the historical development of the EMS/SCLL and outlines its cytogenetic abnormalities and molecular mechanisms with an illustrative case.
机译:8p11骨髓增生异常综合征(EMS),也称为干细胞白血病/淋巴瘤(SCLL),是一种相对罕见的疾病,其典型特征是同时或相继发生bcr / abl阴性骨髓增生性疾病和淋巴瘤,通常是前体T淋巴母细胞淋巴瘤。该疾病通常终止于对常规化学疗法有抵抗力的急性髓细胞性白血病。定义性的细胞遗传学异常(在8p11位点易位)始终涉及成纤维细胞生长因子1(FGFR1)基因。迄今为止,已经鉴定出与FGFR1重排相关的八个伴侣基因。最常见的FGFR1易位伴侣是位于13q11的锌指基因ZNF198。 t(8; 13)(p11; q11)破坏了FGFR1基因的内含子8,并将ZNF198基因的富含脯氨酸和锌指结构域与FGFR1的胞质酪氨酸激酶结构域融合。发生融合蛋白的寡聚化,随后激活下游信号转导途径,最终导致赘生性细胞转化。这篇综述描述了EMS / SCLL的历史发展,并举例说明了其细胞遗传异常和分子机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号